C4 Therapeutics stock jumped after Bristol Myers Squibb announced strong Phase 3 SUCCESSOR-2 results for mezigdomide in multiple myeloma.
Cytokinetics’ (aficamten) met both primary endpoints in the Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy (nHCM). Already approved for obstructive HCM, the drug could soon double its market.
FDA again rejects Replimune’s skin cancer drug RP1, saying studies don’t prove it works; shares halted, setback for company.
Janux Therapeutics announces collaboration with Bristol Myers Squibb to develop novel tumor-activated cancer therapy, with potential payments up to $850 million.
Nine pharmaceutical giants including Merck and GSK agree to slash U.S. drug prices to match other wealthy nations under new Trump administration deals, offering discounts up to 70%.
Bank of America upgrades Bristol Myers Squibb to Buy, raising its price target to $61, citing a strong R&D pipeline and multiple upcoming catalysts through 2026.
